Structure-Based Drug Discovery for Botulinum Neurotoxins
Biology Department, Brookhaven National Laboratory, Upton, NY, 11973, USA, .Current topics in microbiology and immunology (Impact Factor: 4.1). 01/2013; 364:197-218. DOI: 10.1007/978-3-642-33570-9_10
Clostridium botulinum neurotoxin is the most poisonous substance known to humans. It is a potential biowarfare threat and a public health hazard. The only therapeutics available is antibody treatment which will not be effective for post-exposure therapy. There are no drugs available for post-intoxication treatment. Accordingly, it is imperative to develop effective drugs to counter botulism. Available structural information on botulinum neurotoxins both alone and in complex with their substrates offers an efficient method for designing structure-based drugs to treat botulism.
- The Comprehensive Sourcebook of Bacterial Protein Toxins, 01/2006: pages 348-389; , ISBN: 9780120884452
- [Show abstract] [Hide abstract]
ABSTRACT: Botulism is a severe neuroparalytic disease resulting from exposure to one of the most poisonous toxins to humans. Because of this high potency and the use of toxins as biological weapons, botulism is a public health concern and each case represents an emergency. Current therapy involves respiratory supportive care and anti-toxins administration. As a preventive measure, vaccination against toxins represents an effective strategy but is undesirable due the rarity of botulism and the effectiveness of toxins in treating several neuromuscular disorders. This paper summarizes the current issues in botulism treatment and prevention, highlighting the challenge for future researches.Expert Review of Anti-infective Therapy 08/2014; 12(9):1-12. DOI:10.1586/14787210.2014.945917 · 2.25 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.